A Phase I Study of Avelumab Plus Utomilumab-Based Combination Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2018
Price : $35 *
At a glance
- Drugs Avelumab (Primary) ; Ibrutinib (Primary) ; Rituximab (Primary) ; Utomilumab (Primary) ; Carboplatin; Etoposide phosphate; Ifosfamide
- Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 13 Jun 2018 Planned End Date changed from 16 Jun 2020 to 8 Jun 2020.
- 13 Jun 2018 Planned primary completion date changed from 16 Jun 2020 to 8 Jun 2020.